Nuvation Bio Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma

Reuters12-03

<a href="https://laohu8.com/S/NUVB">Nuvation Bio</a> Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma

Nuvation Bio Inc. has announced the publication of positive results from a Phase 2 study evaluating safusidenib, an oral inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The study, published in the journal Neuro-Oncology on November 8, assessed 27 patients and reported an objective response rate of 44.4%, with 87.9% of patients progression-free at 24 months. Median progression-free survival was not reached at a median follow-up of 28 months. The results support ongoing discussions with the FDA regarding the ongoing G203 study, which is being amended into a pivotal global Phase 3 trial in high-grade gliomas. A trial-in-progress poster on the G203 study was presented at the 30th Annual Meeting of the Society for Neuro-Oncology on November 21. A Good Clinical Practice noncompliance issue related to adverse event collection was identified and subsequently addressed through a re-investigation and re-collection of safety data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203703470) on December 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588104625?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588104625","market":"fut","top_or_hot":-1,"title":"Nuvation Bio Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> Inc. has announced the publication of positive results from a Phase 2 study evaluating safusidenib, an oral inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The study, published in the journal Neuro-Oncology on November 8, assessed 27 patients and reported an objective response rate of 44.4%, with 87.9% of patients progression-free at 24 months. Median progression-free survival was not reached at a median follow-up of 28 months. The results support ongoing discussions with the FDA regarding the ongoing G203 study, which is being amended into a pivotal global Phase 3 trial in high-grade gliomas. A trial-in-progress poster on the G203 study was presented at the 30th Annual Meeting of the Society for Neuro-Oncology on November 21. A Good Clinical Practice noncompliance issue related to adverse event collection was identified and subsequently addressed through a re-investigation and re-collection of safety data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203703470) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvation Bio Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvation Bio Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> Inc. has announced the publication of positive results from a Phase 2 study evaluating safusidenib, an oral inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The study, published in the journal Neuro-Oncology on November 8, assessed 27 patients and reported an objective response rate of 44.4%, with 87.9% of patients progression-free at 24 months. Median progression-free survival was not reached at a median follow-up of 28 months. The results support ongoing discussions with the FDA regarding the ongoing G203 study, which is being amended into a pivotal global Phase 3 trial in high-grade gliomas. A trial-in-progress poster on the G203 study was presented at the 30th Annual Meeting of the Society for Neuro-Oncology on November 21. A Good Clinical Practice noncompliance issue related to adverse event collection was identified and subsequently addressed through a re-investigation and re-collection of safety data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203703470) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVB","symbol_name":"Nuvation Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2vzZ4n:1","article_id":"2588104625","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588104625","pubTimestamp":1764766853,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nuvation Bio Inc. has announced the publication of positive results from a Phase 2 study evaluating safusidenib, an oral inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-nave grade 2 IDH1-mutant gliomas. The study, published in the journal Neuro-Oncology on November 8, assessed 27 patients and reported an objective response rate of 44.4%, with 87.9% of patients progression-free at 24 months. Median progression-free survival was not reached at a median follow-up of 28 months. The results support ongoing discussions with the FDA regarding the ongoing G203 study, which is being amended into a pivotal global Phase 3 trial in high-grade gliomas. A trial-in-progress poster on the G203 study was presented at the 30th Annual Meeting of the Society for Neuro-Oncology on November 21. A Good Clinical Practice noncompliance issue related to adverse event collection was identified and subsequently addressed through a re-investigation and re-collection of safety data.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVB":"Nuvation Bio, Inc.","BK4007":"制药"},"translate_title":"Nuvation Bio报告Safusidenib治疗IDH1突变神经胶质瘤的2期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":0.9},"content_text":"Nuvation Bio Reports Positive Phase 2 Results for Safusidenib in IDH1-Mutant Glioma\n    \n\nNuvation Bio Inc. has announced the publication of positive results from a Phase 2 study evaluating safusidenib, an oral inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The study, published in the journal Neuro-Oncology on November 8, assessed 27 patients and reported an objective response rate of 44.4%, with 87.9% of patients progression-free at 24 months. Median progression-free survival was not reached at a median follow-up of 28 months. The results support ongoing discussions with the FDA regarding the ongoing G203 study, which is being amended into a pivotal global Phase 3 trial in high-grade gliomas. A trial-in-progress poster on the G203 study was presented at the 30th Annual Meeting of the Society for Neuro-Oncology on November 21. A Good Clinical Practice noncompliance issue related to adverse event collection was identified and subsequently addressed through a re-investigation and re-collection of safety data.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203703470) on December 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588104625","isCrawlerRequest":true}